Literature DB >> 28963139

PI3Kγ Activates Integrin α4 and Promotes Immune Suppressive Myeloid Cell Polarization during Tumor Progression.

Philippe Foubert1, Megan M Kaneda1, Judith A Varner2,3.   

Abstract

Immunosuppressive myeloid-derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) accumulate in tumors where they inhibit T cell-mediated antitumor immune responses and promote tumor progression. Myeloid cell PI3Kγ plays a role in regulating tumor immune suppression by promoting integrin α4-dependent MDSC recruitment to tumors and by stimulating the immunosuppressive polarization of MDSCs and TAMs. Here, we show that integrin α4 promotes immunosuppressive polarization of MDSCs and TAMs downstream of PI3Kγ, thereby inhibiting antitumor immunity. Genetic or pharmacological suppression of either PI3Kγ or integrin α4 blocked MDSC recruitment to tumors and also inhibited immune suppressive myeloid cell polarization, thereby reducing expression of IL10 and increasing expression of IL12 and IFNγ within tumors. Inhibition of PI3Kγ or integrin α4 within tumors stimulated dendritic cell and CD8+ T-cell recruitment and maturation, as well as tumor cell cytotoxicity in vivo, thereby inhibiting tumor growth. As blockade of PI3Kγ or integrin α4 prevents accumulation of MDSC and reduces myeloid cell expression of immunosuppressive factors that stimulate tumor immune escape, these results highlight PI3Kγ and integrin α4 as targets for the design of cancer therapeutics. Cancer Immunol Res; 5(11); 957-68. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28963139      PMCID: PMC6422969          DOI: 10.1158/2326-6066.CIR-17-0143

Source DB:  PubMed          Journal:  Cancer Immunol Res        ISSN: 2326-6066            Impact factor:   11.151


  23 in total

Review 1.  Phosphoinositide 3-kinase δ is a regulatory T-cell target in cancer immunotherapy.

Authors:  Ee Lyn Lim; Klaus Okkenhaug
Journal:  Immunology       Date:  2019-07       Impact factor: 7.397

2.  The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.

Authors:  Kamira Maharaj; John J Powers; Alex Achille; Melanie Mediavilla-Varela; Wael Gamal; Karen L Burger; Renee Fonseca; Kun Jiang; Hari P Miskin; Dave Maryanski; Andrii Monastyrskyi; Derek R Duckett; William R Roush; John L Cleveland; Eva Sahakian; Javier Pinilla-Ibarz
Journal:  Blood Adv       Date:  2020-07-14

Review 3.  Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives.

Authors:  Umar Mehraj; Hina Qayoom; Manzoor A Mir
Journal:  Breast Cancer       Date:  2021-03-04       Impact factor: 4.239

4.  Metabolism in tumor-associated macrophages.

Authors:  Jie Li; Gina M DeNicola; Brian Ruffell
Journal:  Int Rev Cell Mol Biol       Date:  2022-02-21       Impact factor: 6.420

Review 5.  Macrophages as regulators of tumour immunity and immunotherapy.

Authors:  David G DeNardo; Brian Ruffell
Journal:  Nat Rev Immunol       Date:  2019-06       Impact factor: 53.106

Review 6.  The role of PI3Kγ in the immune system: new insights and translational implications.

Authors:  Stephen M Lanahan; Matthias P Wymann; Carrie L Lucas
Journal:  Nat Rev Immunol       Date:  2022-03-23       Impact factor: 53.106

Review 7.  Maximizing insights from monogenic immune disorders.

Authors:  Anis Barmada; Anjali Ramaswamy; Carrie L Lucas
Journal:  Curr Opin Immunol       Date:  2021-10-22       Impact factor: 7.486

Review 8.  Evolving therapeutic landscape in follicular lymphoma: a look at emerging and investigational therapies.

Authors:  Walter Hanel; Narendranath Epperla
Journal:  J Hematol Oncol       Date:  2021-06-30       Impact factor: 17.388

Review 9.  The therapeutic implications of immunosuppressive tumor aerobic glycolysis.

Authors:  Bradley I Reinfeld; W Kimryn Rathmell; Tae Kon Kim; Jeffrey C Rathmell
Journal:  Cell Mol Immunol       Date:  2021-07-08       Impact factor: 11.530

10.  Interleukin-18 Amplifies Macrophage Polarization and Morphological Alteration, Leading to Excessive Angiogenesis.

Authors:  Takuro Kobori; Shinichi Hamasaki; Atsuhiro Kitaura; Yui Yamazaki; Takashi Nishinaka; Atsuko Niwa; Shinichi Nakao; Hidenori Wake; Shuji Mori; Tadashi Yoshino; Masahiro Nishibori; Hideo Takahashi
Journal:  Front Immunol       Date:  2018-03-06       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.